Back to Search
Start Over
Role of Induction in a Haplomatch, Related, Low-Risk, Living-Donor Kidney Transplantation with Triple Drug Immunosuppression: A Single-Center Study.
- Source :
-
Indian Journal of Nephrology . May/Jun2024, Vol. 34 Issue 3, p246-251. 6p. - Publication Year :
- 2024
-
Abstract
- Background: The role of induction in low-risk, living-donor kidney transplants being treated with tacrolimus, mycophenolate mofetil, and prednisolone is debatable. Materials and Methods: This was a retrospective study that consisted of patients undergoing living kidney transplantation between February 2010 and June 2021 with a related haplomatch donor, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil, and prednisolone. High-risk transplants, such as second or more transplants, immunologically incompatible transplants, and steroid-free transplants, were excluded. Patients were divided into three groups: no induction, basiliximab induction, and thymoglobulin induction, and the outcomes of all three were compared. Results: A total of 350 transplants were performed. There was a significant difference in the recipient sex distribution (P = 0.0373) and the number of preemptive transplants (P = 0.0272) between the groups. Other parameters were comparable. Biopsy-proven acute rejection (BPAR) was significantly less frequent in the thymoglobulin group than in the no-induction (5.3% vs. 17.5%; P = 0.0051) or basiliximab (5.3% vs. 18.8%; P = 0.0054) group. This persisted even after we performed multivariate regression analysis (thymoglobulin vs. no-induction group, P = 0.0146; thymoglobulin vs. basiliximab group, P = 0.0237). There was no difference in BPAR between the basiliximab and no-induction groups. There were no differences in other outcomes between the groups. Conclusion: In a low-risk haplomatch, related, living-donor kidney transplant on tacrolimus, mycophenolate mofetil, and prednisolone, BPAR was significantly lower with thymoglobulin as opposed to no induction or basiliximab induction with a similar short-term patient and death-censored graft survival and infection rates. Basiliximab did not provide any benefit over no induction. [ABSTRACT FROM AUTHOR]
- Subjects :
- *KIDNEY transplantation
*ORGAN donors
*HEMATOPOIETIC stem cell transplantation
*RISK assessment
*PATIENTS
*TRANSPLANTATION of organs, tissues, etc.
*T-test (Statistics)
*RESEARCH funding
*MYCOPHENOLIC acid
*MULTIPLE regression analysis
*FISHER exact test
*RETROSPECTIVE studies
*DESCRIPTIVE statistics
*PREDNISOLONE
*MANN Whitney U Test
*KAPLAN-Meier estimator
*LOG-rank test
*MEDICAL records
*ACQUISITION of data
*TACROLIMUS
*ANALYSIS of variance
*COMPARATIVE studies
*DATA analysis software
*IMMUNOSUPPRESSION
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09714065
- Volume :
- 34
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Indian Journal of Nephrology
- Publication Type :
- Academic Journal
- Accession number :
- 179011182
- Full Text :
- https://doi.org/10.4103/ijn.ijn_84_23